A Study of WVT078 in Patients With Multiple Myeloma

Overview

The design of a phase I, open-label, dose finding study was chosen in order to establish a safe and tolerated dose of single agent WVT078 alone and in combination with WHG626 in patients relapses and/or refractory Multiple Myeloma (MM)

SparkCures ID 1080
Trial Phase Phase 1
Enrollment 90 Patients
Treatments
  • WHG626
  • WVT078
Tags
Trial Sponsors
  • Novartis
NCT Identifier

NCT04123418

ACCEPTING

This trial is currently open and accepting patients.

Am I Eligible?

The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.

Inclusion Criteria:

  • Subjects who are relapsed and/or refractory to two or more regimens including an IMID, proteasome inhibitor, and an anti-CD38 agent (if available)

Exclusion Criteria:

  • Use of systemic chronic steroid therapy (>or= 10mg/day prednisone or equivalent) or any immunosuppressive therapy within 7 days of first dose of study treatment
  • Malignant disease other than being treated on this study
  • Active known or suspected autoimmune disease
  • Impaired cardiac function or clinically significant cardiac disease
  • Treatment with cytotoxic or small molecule antineoplastics or any experimental therapy within 14 days or 5 half-lives whichever is shorter
  • Active central nervous system involvement by malignancy or presence of symptomatic CNS metasteses

The following criteria is provided for health care professionals.

Inclusion Criteria:

  • Subjects who are relapsed and/or refractory to two or more regimens including an IMID, proteasome inhibitor, and an anti-CD38 agent (if available)

Exclusion Criteria:

  • Use of systemic chronic steroid therapy (>or= 10mg/day prednisone or equivalent) or any immunosuppressive therapy within 7 days of first dose of study treatment
  • Malignant disease other than being treated on this study
  • Active known or suspected autoimmune disease
  • Impaired cardiac function or clinically significant cardiac disease
  • Treatment with cytotoxic or small molecule antineoplastics or any experimental therapy within 14 days or 5 half-lives whichever is shorter
  • Active central nervous system involvement by malignancy or presence of symptomatic CNS metasteses
🤔 Am I Eligible?

Understanding this criteria can be difficult - call us today.

(888) 828-2206 Create My Account

US Trial Locations

Accepting Patients

The following is a listing of trial locations that are open and accepting patients.

Verified Winship Cancer Institute of Emory University
Winship Cancer Institute of Emory University

Atlanta, GA

Verified Medical College of Wisconsin Froedtert Hospital
Medical College of Wisconsin Froedtert Hospital

Milwaukee, WI

SparkCures Verified Accurate, up-to-date information. Learn more

Mayo Clinic (Rochester)

Rochester, MN

Georgia
Verified Winship Cancer Institute of Emory University
Winship Cancer Institute of Emory University

Atlanta, GA

  • Recruiting

SparkCures Verified Accurate, up-to-date information. Learn more

Minnesota
Mayo Clinic (Rochester)

Rochester, MN

  • Recruiting
Wisconsin
Verified Medical College of Wisconsin Froedtert Hospital
Medical College of Wisconsin Froedtert Hospital

Milwaukee, WI

  • Recruiting

SparkCures Verified Accurate, up-to-date information. Learn more

International Locations

This trial has active trial locations in countries outside of the United States.

Our system currently only provides clinical trial matching services for myeloma patients in the United States.

You can view this clinical trial's international locations by visiting ClinicalTrials.gov. Please be aware that the government website may include information that is inaccurate and/or out-of-date.

View International Centers

Resources

There are no resources, links or videos to display for this clinical trial.

Interested in this trial?
  • Call us today 😀 keyboard_arrow_right

    We know how difficult and confusing this process can be. If you are interested in this clinical trial or have questions, you can call us at any time. You can also send us a direct message with questions.

    (888) 828-2206
  • Add this trial to your favorites keyboard_arrow_right

    If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.

  • Talk to your doctor keyboard_arrow_right

    You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.

Still need help? Send us a message